Pimodivir
Pimodivir (VX-787, JNJ-63623872) is an antiviral drug which was developed as a treatment for influenza. It acts as an inhibitor of influenza virus polymerase basic protein 2, and has shown promising results in Phase II clinical trials. However, in late 2021, Janssen announced that the clinical development of pimidivir had been halted due to lack of benefit over standard of care. See also * Baloxavir marboxil * Favipiravir * Galidesivir * Nitazoxanide * Oseltamivir * Peramivir * Remdesivir * Ribavirin * Triazavirin * Umifenovir * Zanamivir Zanamivir is a medication used to treat and prevent influenza caused by influenza A and influenza B viruses. It is a neuraminidase inhibitor and was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and ap ... References Anti–RNA virus drugs Antiviral drugs {{antiinfective-drug-stub ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]